Secondary acute myelogenous leukemia following treatment with oral etoposide.
Katato
K
K
Flaherty
L
L
Varterasian
M
M
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D004961:Estramustine / Q000009:adverse effects; D005047:Etoposide / Q000009:adverse effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced*; D008297:Male; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D004961:Estramustine; D005047:Etoposide